Blood pressure lowering significantly reduces vascular risk across various baseline blood pressure levels and co-morbidities, according a new report published in the Lancet.
According to the study lowering systolic blood pressures to less than 130 mm Hg and providing blood pressure lowering treatment to people with a history of cardiovascular disease, coronary heart disease, stroke, diabetes, heart failure and chronic kidney disease.
Researcher Kazem Rahimi said:"Our findings clearly show that treating blood pressure to a lower level than currently recommended could greatly reduce the incidence of cardiovascular disease and potentially save millions of lives if the treatment was widely implemented. We would probably be talking about recommending medication for two in four adults – about half the adult population."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze